Overall Success In the Treatment of Hemophilia

Updates from the 55th ASH? – the Annual Meeting of the American Society of Hematology, being held in New Orleans, December 7 – 10, 2013.  The annual meeting is the premier hematology meeting in the world.  

Geoff Watts interviews several international physicians and discusses the latest developments in research and treatment on hemophilia and how this impact everyday clinical practice. In this program:

Overall Success In the Treatment of Hemophilia.

In this interview: Charles Nakar, MD from the Indiana Hemophilia & Thrombosis Center in Indianapolis, IN, USA, Stephanie R Earnshaw, Ph.D, VP Health Economics at RTI Health Solutions, Research Triangle Park, NC, USA, and Etiena Basner-Tschakarjan, MD, Ph.D, Children’s Hospital of Philadelphia, Pediatrics – Hematology, Philadelphia, PA
USA, discuss:

  • Prompt immune tolerance induction at inhibitor diagnosis regardless of titer: does this increase overall success in Hemophilia A with inhibitors?
  • Which three approaches are being used to treat patients with severe hemophilia A and inhibitors, and what cost-efficient strategy is therefore desirable?
  • What cellular immune responses can be seen for Hemophilia B using a self-complementary factor IX vector?

Other programs in this series:

  • Novel Therapeutic Options in the Treatment of Hemophilia [Video]

These interviews were produced in collaboration with


Copyright ? 2013 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.